Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | EP300 | Q09472 | 6/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | SIRT2 | Q8IXJ6 | 5/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PHGDH | O43175 | 1/20 | 0.33 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.33 |
| ▸ | EEF2K | O00418 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2787652 | 0.83 | CYP19A1 (0.36) | CYP19A1PHGDHACSS2 | |
| SCHEMBL2787655 | 0.83 | CYP19A1 (0.36) | CYP19A1PHGDHACSS2 | |
| SCHEMBL2917462 | 0.81 | PTGDR2 (0.35) | EP300MAPTKDM4EGAAL3MBTL1 | |
| SCHEMBL8156285 | 0.78 | TSHR (0.37) | CYP19A1SIRT2PHGDHACSS2 | |
| SCHEMBL7848579 | 0.77 | CPB2 (0.43) | SIRT2 | |
| SCHEMBL8147915 | 0.76 | FNTA (0.36) | CYP19A1SIRT2ACSS2 | |
| SCHEMBL8147914 | 0.76 | FNTA (0.36) | CYP19A1SIRT2ACSS2 | |
| SCHEMBL2913313 | 0.75 | SIRT2 (0.35) | GAAL3MBTL1SIRT2SMN1; SMN2 | |
| SCHEMBL2909984 | 0.74 | SIRT2 (0.34) | SIRT2 | |
| SCHEMBL4756365 | 0.74 | SIRT2 (0.40) | CYP19A1SIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076327-B2 | Condensed imidazole derivatives as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2011-12-13 | — | — | US | disclosed |
| US-20100305110-A1 | CONDENSED IMIDAZOLE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2010-12-02 | — | — | US | disclosed |
| US-7799780-B2 | Condensed imidazole derivatives as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2010-09-21 | — | — | US | disclosed |
| EP-2004657-B1 | CONDENSED IMIDAZOLE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2010-09-01 | — | — | EP | disclosed |
| US-20090012068-A1 | Condensed Imidazole Derivatives as Aldosterone Synthase Inhibitors | NOVARTIS AG (CH) | 2009-01-08 | — | — | US | disclosed |
| EP-2004657-A1 | CONDENSED IMIDAZOLE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | Speedel Experimenta AG (CH) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007116097-A1 | CONDENSED IMIDAZOLE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012068-A1 | Condensed Imidazole Derivatives as Aldosterone Synthase Inhibitors | CYP11B1, CYP11B2, REN | HTT 4809/4885EP300 449/4885MAPT 3834/4885 |
| US-20100305110-A1 | CONDENSED IMIDAZOLE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | CYP11B1, CYP11B2, REN | HTT 4813/4885EP300 457/4885MAPT 3844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.